Drug Interactions between bebtelovimab and sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine

The immunogenicity and efficacy of SARS-CoV-2 (COVID-19) vaccines in individuals who have previously received passive antibody therapy (e.g., monoclonal antibodies, convalescent plasma) as part of COVID-19 treatment or for post-exposure or pre-exposure prophylaxis have not been fully evaluated. The U.S. Centers for Disease Control and Prevention (CDC), as well as immunization guidelines available from other countries like the United Kingdom, advise that COVID-19 vaccination may be given at any time to such individuals and does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Previously, it was recommended to defer COVID-19 vaccination for 30 days after receiving passive antibody therapy for post-exposure prophylaxis and for 90 days after treatment for COVID-19 as a precautionary measure to avoid potential interference of the antibody therapy with vaccine-induced immune response. Although some reduction in vaccine-induced antibody titers was observed in individuals who previously received antibody products, the clinical significance of this reduction is unknown. Some authorities suggest that the balance of benefits versus risks favors proceeding with vaccination, even considering the possibility of diminished vaccine effectiveness.

Switch to consumer interaction data